Compare Natera Inc. Common Stock (NTRA) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SYSCO Corporation — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while SYSCO Corporation trades at $82 (market cap $39.83B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and SYSCO Corporation pays a 2.72% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SYSCO Corporation for 78 Days on average.
| NTRA | SYY | |
|---|---|---|
Market Cap | $57.03B | $39.83B |
Volume | 1,131,157 | 2,622,881 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $91.16 |
52-Week Low | $179.42 | $69.30 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $56.18B | $53.01B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SYY trades at $79.03, up 0.42% with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $81.37B in 2025 but faces margin pressure with net income margin at 2.08%. Analyst consensus remains bullish with a $85.75 price target, supported by a $500M AI efficiency program announced in September 2026. Cash flow improved to $403M net inflow in 2025, though debt levels remain elevated at 49.75% debt-to-assets.
SYY offers value with low P/S of 0.45 and strong institutional support, but high P/E of 21.59 and technical bearishness suggest near-term volatility. The AI initiative and dividend yield provide upside catalysts, while margin compression and competitive pressures pose risks to earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
